One in four people will develop a mental health problem at some point during their lives. Mental distress can range from mild depression or anxiety to conditions such as bipolar disorder (manic depression) or schizophrenia where individuals may experience psychosis.
The Institute of Mental Health was launched in 2006 to help transform our understanding and treatment of mental illness. We are a partnership between Nottinghamshire Healthcare NHS Trust and the University of Nottingham and we are one of the leading mental health institutes in the UK, offering leadership and innovation backed by world class expertise.
Although many medicines are used to treat bi-polar depression there is still little reliable evidence to help patients and doctors to select the drug or combination of drugs that is likely to be the most effective, safe and tolerable. CEQUEL is a randomised controlled trial designed to provide strong and reliable evidence on the effect of adding Lamotrigine to Quetiapine and of adding Folic Acid to treatments for bi-polar depression. The trial will also explore links between genetic factors and response to folic acid treatment.
Across both Nottinghamshire and Lincolnshire, Clinical Studies Officers from the National Institute for Health Research Mental Health Research Network, have initiated several psychiatrists to act as investigators for the study. Investigators will be responsible for screening, recruiting and conducting trial procedures with potential participants from their caseloads. Those considered eligible will be aged 16 or over, currently depressed, about to start new treatment for depression and uncertainty remains about which treatment would be most effective.
The study is currently seeking participants and is being supported by staff from the East Midlands Hub of the MHRN (David Trevor in Nottinghamshire 0115 823 1283 and Alex Satchwell in Lincolnshire 0152 922 2207).
The Oxford Clinical Trials Unit is the trial team conducting the study with sponsorship being provided by the University of Oxford and funding by the UK Medical Research Council.